TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35604482

Group type: EXPERIMENTAL
Intervention: Continuous practice group (unsupervised at home every two weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No-practice group
Number of subjects: 38
Study: 32914847

Group type: EXPERIMENTAL
Intervention: Noise60
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Noise120
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Noise60 and Noise120
Number of subjects: 70
Study: 34383228

Group type: EXPERIMENTAL
Intervention: Letter communicating collateral findings from a pragmatic clinical trial
Number of subjects: 4080

Group type: COMPARATOR
Intervention: Letters that included a description of the clinical trial
Number of subjects: 4080
Study: 35792493

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg BID
Number of subjects: 1157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1157
Study: 33870448

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 0
Study: 33493011

Group type: EXPERIMENTAL
Intervention: Low-Dose Aspirin (LDA) for 5 of 7 days per week
Number of subjects: 1227

Group type: COMPARATOR
Intervention: Postconception initiation of LDA therapy
Number of subjects: 1227
Study: 34320428

Group type: EXPERIMENTAL
Intervention: 75 J.cm−2 LED, 600 μmol.L−1 curcumin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 600 μmol.L−1 curcumin plus 17% EDTA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 600 μmol.L−1 curcumin plus 18% HEBP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 600 μmol.L−1 curcumin plus 75 J.cm−2 LED
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 600 μmol.L−1 curcumin plus 17% EDTA and 75 J.cm−2 LED
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 600 μmol.L−1 curcumin plus 18% HEBP and 75 J.cm−2 LED
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 34529859

Group type: EXPERIMENTAL
Intervention: LED treatment (590, 630, and 850 nm with two tested irradiances each)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 10
Study: 32176657

Group type: EXPERIMENTAL
Intervention: Individually Tailored Internet-Based Cognitive Behavioral Therapy (ICBT) combined with standard medical treatment
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard medical treatment plus being on waitlist to ICBT (CONTROL)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Individually Tailored Internet-Based Cognitive Behavioral Therapy (ICBT)
Number of subjects: 77
Study: 35412032

Group type: EXPERIMENTAL
Intervention: Budesonide orodispersible tablet (BOT) 1 mg BID for 6 weeks
Number of subjects: 181
Study: 33638144

Group type: EXPERIMENTAL
Intervention: Mini PCNL
Number of subjects: 50

Group type: COMPARATOR
Intervention: RIRS
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 50
Study: 34225765

Group type: EXPERIMENTAL
Intervention: Sodium valproate (VPA) for 4 months
Number of subjects: 110

Group type: COMPARATOR
Intervention: Observation only for 4 months
Number of subjects: 110
Study: 33933921

Group type: EXPERIMENTAL
Intervention: Screening and notifying the primary care provider (PCP)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Screening, notifying the PCP, and providing enhanced depression treatment
Number of subjects: 1500

Group type: COMPARATOR
Intervention: No screening
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Screen and Notify vs No Screen
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 1500
Study: 35339669

Group type: EXPERIMENTAL
Intervention: Double-blind peppermint oil (DBM)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Double-blind placebo (DBP)
Number of subjects: 173
Study: 33589408

Group type: EXPERIMENTAL
Intervention: MitraClip plus maximally tolerated guideline‐directed medical therapy (GDMT)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: MitraClip
Number of subjects: 575

Group type: COMPARATOR
Intervention: GDMT alone
Number of subjects: 575
Study: 32820838

Group type: EXPERIMENTAL
Intervention: EB-HF (energy balance with high fat)
Number of subjects: 9

Group type: COMPARATOR
Intervention: ED-LF (energy deficit with low fat)
Number of subjects: 9
Study: 35354299

Group type: EXPERIMENTAL
Intervention: Rigorous preclinical assessment with treatment masking, randomization, and blinded assessment.
Number of subjects: 913

Group type: EXPERIMENTAL
Intervention: Standardized procedural implementation across laboratories.
Number of subjects: 913

Group type: COMPARATOR
Intervention: Randomized, placebo-controlled, blinded trial design.
Number of subjects: 913
Study: 32428843

Group type: EXPERIMENTAL
Intervention: Aquatic exercise twice a week (2x/w)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aquatic exercise three times a week (3x/w)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Active control condition (ACC)
Number of subjects: 60
Study: 34896280

Group type: EXPERIMENTAL
Intervention: Mindfulness-based music therapy intervention (4 sessions over 12 weeks)
Number of subjects: 37
Study: 32648081

Group type: EXPERIMENTAL
Intervention: Aortic valve replacement (AVR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 0
Study: 36441220

Group type: EXPERIMENTAL
Intervention: Limited tourniquet (LT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional tourniquet (CT)
Number of subjects: 100
Study: 33826537

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (DES)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Drug-coated balloons (DCB)
Number of subjects: 53
Study: 35636734

Group type: EXPERIMENTAL
Intervention: Acting with Mindfulness for Pain (AMP)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 86
Study: 34090515

Group type: EXPERIMENTAL
Intervention: Pediatric integrative manual therapy (PIMT) plus caregiver education program
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (caregiver education program only)
Number of subjects: 34
Study: 34650004

Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Number of subjects: 142

Group type: COMPARATOR
Intervention: Pulmonary rehabilitation
Number of subjects: 142
Study: 33907210

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) applied with a GaAlAs laser (wavelength=810 nm) at pre-determined points in the masseter muscle (6 J/cm2, 3 regions, 60 s) or TMJ region (6 J/cm2, 5 points, 30 s) for 7 consecutive days.
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo treatment for 7 consecutive days.
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 175
Study: 33984725

Group type: EXPERIMENTAL
Intervention: Postoperative dose-dense adjuvant chemotherapy with bevacizumab maintenance after neoadjuvant chemotherapy
Number of subjects: 22
Study: 32340471

Group type: EXPERIMENTAL
Intervention: Galcanezumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36073608

Group type: EXPERIMENTAL
Intervention: Sini powder (SNP)
Number of subjects: 36
Study: 34626843

Group type: EXPERIMENTAL
Intervention: Ultrabrief pulse width (UB: 0.3 ms) ECT
Number of subjects: 9

Group type: COMPARATOR
Intervention: Brief pulse width (BP: 1.0 ms) ECT with frontoparietal (FP) placement
Number of subjects: 9

Group type: COMPARATOR
Intervention: Higher E-fields in regions-of-interest with TP ECT
Number of subjects: 9
Study: 32562573

Group type: EXPERIMENTAL
Intervention: 100 mg daily low-dose aspirin
Number of subjects: 13547

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13547
Study: 34028506

Group type: EXPERIMENTAL
Intervention: Bariatric Surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community Weight Management Intervention
Number of subjects: 0
Study: 33225834

Group type: EXPERIMENTAL
Intervention: 3D CMIE
Number of subjects: 98

Group type: COMPARATOR
Intervention: 2D CMIE
Number of subjects: 98
Study: 33686753

Group type: EXPERIMENTAL
Intervention: Abemaciclib + endocrine therapy (ET) in MONARCH 2
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Abemaciclib + endocrine therapy (ET) in MONARCH 3
Number of subjects: 356

Group type: COMPARATOR
Intervention: Adverse events in MONARCH 2
Number of subjects: 356

Group type: COMPARATOR
Intervention: Adverse events in MONARCH 3
Number of subjects: 356
Study: 33378517

Group type: EXPERIMENTAL
Intervention: Xylitol-containing toothbrushes
Number of subjects: 44

Group type: COMPARATOR
Intervention: Xylitol-free toothbrushes (Control)
Number of subjects: 44
Study: 33896276

Group type: EXPERIMENTAL
Intervention: Dolutegravir + ritonavir-boosted darunavir (2DR)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Standard-of-care therapy with two nucleoside reverse transcriptase inhibitors + DRV/r (3DR)
Number of subjects: 263
Study: 33418367

Group type: EXPERIMENTAL
Intervention: Bio-psycho-social treatment programme (6-7 months)
Number of subjects: 321
Study: 32068890

Group type: EXPERIMENTAL
Intervention: CNN-based classifier
Number of subjects: 24667

Group type: COMPARATOR
Intervention: Clinical visual assessments (CVAs) by 12 otolaryngologists
Number of subjects: 24667
Study: 34985366

Group type: EXPERIMENTAL
Intervention: rPMS (20Hz and 2400 pulses to triceps brachii and extensor digitorum muscles daily for two weeks in addition to conventional physiotherapy)
Number of subjects: 44
Study: 33513313

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus ipilimumab
Number of subjects: 568

Group type: COMPARATOR
Intervention: Pembrolizumab plus placebo
Number of subjects: 568
Study: 32412970

Group type: EXPERIMENTAL
Intervention: Unstable resistance training (uRT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Stable resistance training (sRT)
Number of subjects: 55
Study: 33497833

Group type: EXPERIMENTAL
Intervention: mPCST-Community
Number of subjects: 180

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 180
Study: 34503850

Group type: EXPERIMENTAL
Intervention: Open total gastrectomy (OTG)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Minimally invasive total gastrectomy (MITG)
Number of subjects: 96
Study: 33285037

Group type: EXPERIMENTAL
Intervention: Viltolarsen 40 mg/kg/week
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Viltolarsen 80 mg/kg/week
Number of subjects: 16
Study: 34394103

Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard of care (non-exercised group)
Number of subjects: 14
Study: 33077839

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (ACT) after radical nephroureterectomy (RNU)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: RNU + ACT
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: RNU + ACT in T3/4 cohort
Number of subjects: 176

Group type: COMPARATOR
Intervention: RNU
Number of subjects: 176
Study: 33655812

Group type: EXPERIMENTAL
Intervention: Non-linear periodized resistance training (NLP)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Linear periodized resistance training (LP)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Both LP and NLP
Number of subjects: 28
Study: 33235349

Group type: EXPERIMENTAL
Intervention: Teller Acuity Cards II
Number of subjects: 0
Study: 32212282

Group type: EXPERIMENTAL
Intervention: Real-world evidence (RWE) studies
Number of subjects: 7267

Group type: EXPERIMENTAL
Intervention: RWE studies categorized as medical records
Number of subjects: 7267

Group type: EXPERIMENTAL
Intervention: RWE for gastroenterological diseases
Number of subjects: 7267

Group type: EXPERIMENTAL
Intervention: RWE for respiratory diseases
Number of subjects: 7267

Group type: EXPERIMENTAL
Intervention: RWE for older drugs
Number of subjects: 7267
Study: 35980080

Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (IMN)
Number of subjects: 240

Group type: COMPARATOR
Intervention: External fixation (EF)
Number of subjects: 240
Study: 33543484

Group type: EXPERIMENTAL
Intervention: Propolis (n = 91)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo (n = 42)
Number of subjects: 133
Study: 33402248

Group type: EXPERIMENTAL
Intervention: Health warning labels (HWLs) placed on waterpipe (stem, water bowl, hose)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Health warning labels (HWLs)
Number of subjects: 74
Study: 35018094

Group type: EXPERIMENTAL
Intervention: N‐AbA 300 mg
Number of subjects: 76

Group type: COMPARATOR
Intervention: R‐AbA 1000 mg
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: N‐AbA on a high-fat diet
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: N‐AbA and SNAC
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: SNAC
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Food effect on N‐AbA
Number of subjects: 76
Study: 33768581

Group type: EXPERIMENTAL
Intervention: Local Message
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Nutrition Message
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control
Number of subjects: 160
Study: 32464936

Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (DA)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (no dopamine)
Number of subjects: 82
Study: 36256630

Group type: EXPERIMENTAL
Intervention: Cesarean delivery (CD)
Number of subjects: 737904
Study: 35001668

Group type: EXPERIMENTAL
Intervention: Thai traditional massage for 4 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg daily
Number of subjects: 45
Study: 34736388

Group type: EXPERIMENTAL
Intervention: Active rTMS (n=40)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Sham rTMS (n=49)
Number of subjects: 89
Study: 33985532

Group type: EXPERIMENTAL
Intervention: PLAN-A intervention (peer-led physical activity program)
Number of subjects: 1558

Group type: COMPARATOR
Intervention: Non-intervention control group
Number of subjects: 1558
Study: 35689208

Group type: EXPERIMENTAL
Intervention: Remimazolam tosilate (RT) 0.15 mg/kg with supplemental doses of 0.05 mg/kg as needed
Number of subjects: 82

Group type: COMPARATOR
Intervention: Propofol 1.5 mg/kg with supplemental doses of 0.5 mg/kg
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Remimazolam tosilate (RT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 82
Study: 34544853

Group type: EXPERIMENTAL
Intervention: 20 extra hours of self-selected, task-specific motor therapy starting at 2 to 3 months after stroke (subacute group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 extra hours of self-selected, task-specific motor therapy starting at ?30 days after stroke (acute group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 extra hours of self-selected, task-specific motor therapy starting at ?6 months after stroke (chronic group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard motor rehabilitation (control group)
Number of subjects: 0
Study: 35157791

Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg 3 times daily
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Domperidone 20 mg 3 times daily
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 44
Study: 34969405

Group type: EXPERIMENTAL
Intervention: Blood flow restriction associated with passive mobilization (BFRp)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Blood flow restriction associated with electrical stimulation (BFRpE)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Passive mobilization (PM)
Number of subjects: 39
Study: 36367009

Group type: EXPERIMENTAL
Intervention: Microbiome supporting (MS) products
Number of subjects: 14

Group type: COMPARATOR
Intervention: Benchmark (BM) products
Number of subjects: 14
Study: 32145405

Group type: EXPERIMENTAL
Intervention: Sleep condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wake condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modeling parameter considering accuracy and response time
Number of subjects: 0
Study: 34730989

Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy
Number of subjects: 387

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 387
Study: 34161979

Group type: EXPERIMENTAL
Intervention: Early ICU aftercare practices (dietary restrictions, bed rest orders, bladder catheter, advance directive documentation, dysphagia, functional decline, delirium)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Higher Charlson Comorbidity Index
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Midodrine use on medical units
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation in the ICU
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Bladder catheters
Number of subjects: 151
Study: 32056158

Group type: EXPERIMENTAL
Intervention: Cumulative duration of intraoperative hypotension (SAP < 80% pre-induction value)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Mean Comprehensive Complication Index
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Lowest absolute SAP
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Lowest absolute MAP
Number of subjects: 52
Study: 35135684

Group type: EXPERIMENTAL
Intervention: Early artificial rupture of membranes
Number of subjects: 160

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 160
Study: 33798763

Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 1, 2, and 3 mA for 15, 20, and 30 min
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 3 mA for 20 min
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 3 mA for 30 min
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 32
Study: 32055820

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory diet
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control diet (similar to general dietary intake in Sweden)
Number of subjects: 50
Study: 35108059

Group type: EXPERIMENTAL
Intervention: Durvalumab (10 mg/kg intravenously; administered once every 2 weeks for 12 months)
Number of subjects: 713

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 713
Study: 34802961

Group type: EXPERIMENTAL
Intervention: Percutaneous mitral valve repair (pMVR)
Number of subjects: 144
Study: 35289303

Group type: EXPERIMENTAL
Intervention: No stenting
Number of subjects: 603

Group type: COMPARATOR
Intervention: Immediate stenting
Number of subjects: 603
Study: 34653557

Group type: EXPERIMENTAL
Intervention: HIIT+RT (high-intensity interval training combined with resistance training), n=12
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MICT+RT (moderate-intensity continuous training combined with resistance training), n=13
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RT (resistance training alone), n=15
Number of subjects: 40
Study: 34649223

Group type: EXPERIMENTAL
Intervention: Remdesivir (200 mg on the first day followed by 100 mg daily for the next 9 days intravenously infused over 30‐60 minutes) in addition to standard care
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 200
Study: 36396600

Group type: EXPERIMENTAL
Intervention: Progressive moderate-vigorous elastic resistance training (2 days/week for 8 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (usual daily activities for 8 weeks)
Number of subjects: 20
Study: 32845388

Group type: EXPERIMENTAL
Intervention: Nomogram based on US radiomics analysis
Number of subjects: 343
Study: 36038172

Group type: EXPERIMENTAL
Intervention: Vitamin D3 bolus (180,000 IU) maintained by daily dose of 2000 IU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zinc gluconate (40 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D3 and Zinc
Number of subjects: 0
Study: 34520841

Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy (PPV)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Pneumatic retinopexy (PnR)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: PPV with ORFs
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: PPV without ORFs
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Patients with ORFs
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Patients without ORFs
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: PPV
Number of subjects: 88
Study: 35217796

Group type: EXPERIMENTAL
Intervention: LSD 100 µg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: LSD 200 µg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Psilocybin 15 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Psilocybin 30 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: LSD (both doses)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Psilocybin
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: LSD
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both LSD and psilocybin
Number of subjects: 28
Study: 35311437

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Health Education (HAP-E)
Number of subjects: 182
Study: 32962906

Group type: EXPERIMENTAL
Intervention: Reverse Sugar Tong splint (RST)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Below Arm Cast (BAC)
Number of subjects: 140
Study: 32616248

Group type: EXPERIMENTAL
Intervention: Phytase (2,000 FTU/kg) with 0.12% nonphytate phosphorus (nPP)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Inorganic phosphate rock supplementation (0.05‐0.30% extra nPP)
Number of subjects: 504
Study: 616788766

Group type: EXPERIMENTAL
Intervention: Massage therapy with Jasmine oil
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Aroma therapy with Jasmine oil
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 120
Study: 36109691

Group type: EXPERIMENTAL
Intervention: Droperidol (1 mg) + Dexamethasone (5 mg)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Tropisetron (5 mg) + Dexamethasone (5 mg)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Dexamethasone (5 mg) + Saline (5 ml)
Number of subjects: 192
Study: 34157193

Group type: EXPERIMENTAL
Intervention: Real group (rTMS at 10 Hz and 100% motor threshold)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 56